Quarterly report pursuant to Section 13 or 15(d)

IN-LICENSING AND ACQUISITION - Narrative (Details)

v3.24.1.u1
IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 22, 2024
Jul. 27, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2023
Asset Acquisition [Line Items]              
Research and development     $ 6,026 $ 10,089      
Intangible asset     $ 28,863       $ 13,878
Forma              
Asset Acquisition [Line Items]              
Upfront fee   $ 2,000          
Research and development           $ 2,000  
Forma | Commercial milestones              
Asset Acquisition [Line Items]              
Potential payments   165,500          
Forma | Development and regulatory milestones              
Asset Acquisition [Line Items]              
Potential payments   $ 67,500          
Forma | Achievement of certain near-term regulatory milestone              
Asset Acquisition [Line Items]              
Research and development         $ 2,500    
GAVRETO (pralsetinib)              
Asset Acquisition [Line Items]              
Intangible assets, estimated useful life     12 years        
REZLIDHIA              
Asset Acquisition [Line Items]              
Intangible assets, estimated useful life     14 years        
REZLIDHIA | Forma | FDA approval and first commercial sale of product              
Asset Acquisition [Line Items]              
Intangible asset         $ 15,000 $ 15,000  
Blueprint              
Asset Acquisition [Line Items]              
Asset purchase agreement, drug product inventories     $ 7,000        
Drug product inventories received     3,100        
Blueprint | GAVRETO (pralsetinib)              
Asset Acquisition [Line Items]              
Asset acquisition, expected price $ 15,000            
Acquisition related liabilities, transaction cost     200        
Asset acquisition transaction cost paid in cash     $ 100        
Blueprint | GAVRETO (pralsetinib) | Minimum              
Asset Acquisition [Line Items]              
Potential tiered royalties (as a percentage) 10.00%            
Blueprint | GAVRETO (pralsetinib) | Maximum              
Asset Acquisition [Line Items]              
Potential tiered royalties (as a percentage) 30.00%            
Blueprint | GAVRETO (pralsetinib) | First commercial sale              
Asset Acquisition [Line Items]              
Asset acquisition, expected price $ 10,000            
Blueprint | GAVRETO (pralsetinib) | First anniversary of the closing date              
Asset Acquisition [Line Items]              
Asset acquisition, expected price 5,000            
Blueprint | GAVRETO (pralsetinib) | Commercial milestones              
Asset Acquisition [Line Items]              
Potential milestone payments 97,500            
Blueprint | GAVRETO (pralsetinib) | Regulatory milestones              
Asset Acquisition [Line Items]              
Potential milestone payments $ 5,000